Daxor Corporation (DXR)
7.49
-0.46 (-5.79%)
At close: Apr 15, 2025, 3:26 PM
7.87
5.15%
After-hours: Apr 15, 2025, 04:45 PM EDT
-5.79% (1D)
| Bid | 7.31 |
| Market Cap | 36.21M |
| Revenue (ttm) | 154.2K |
| Net Income (ttm) | 1.69M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -83.18 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 8.48 |
| Volume | 10,734 |
| Avg. Volume (20D) | 6,778 |
| Open | 8.00 |
| Previous Close | 7.95 |
| Day's Range | 7.37 - 8.19 |
| 52-Week Range | 6.55 - 10.00 |
| Beta | -0.06 |
About DXR
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation...
Industry Medical - Instruments & Supplies
Sector Healthcare
IPO Date Jul 25, 1983
Employees 37
Stock Exchange NASDAQ
Ticker Symbol DXR
Website https://www.daxor.com
Analyst Forecast
According to 1 analyst ratings, the average rating for DXR stock is "Strong Buy." The 12-month stock price forecast is $25, which is an increase of 233.94% from the latest price.
Stock Forecasts
